Omeros Stock Gains 52% On Successful Trial Results

Dow Jones
2024-12-19

By Katherine Hamilton

Omeros shares gained Thursday after the company shared positive results for a trial of its treatment of a stem-cell transplantation complication.

The stock rose 52% to $11.15. It has nearly doubled over the past month and a half after reporting third-quarter earnings in mid-November.

The Seattle-based biopharmaceutical company said its narsoplimab treatment met its primary endpoint in a trial.

Narsoplimab is a monoclonal antibody designed to treat a complication in stem-cell transplantation called hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA).

The trial compared the survival rate of 28 patients with more than 100 patients in a control group who did not receive narsoplimab. Patients receiving the treatment showed significantly better survival rates.

Omeros plans to resubmit a biologics license application for its narsoplimab to the Food and Drug Administration as soon as possible, it said. If approved, narsoplimab would be the first approved treatment for TA-TMA, Omeros said.

Write to Katherine Hamilton at katherine.hamilton@wsj.com

 

(END) Dow Jones Newswires

December 19, 2024 10:56 ET (15:56 GMT)

Copyright (c) 2024 Dow Jones & Company, Inc.

免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。

熱議股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10